Repurposing the FDA-approved anthelmintic pyrvinium pamoate for pancreatic cancer treatment: study protocol for a phase I clinical trial in early-stage pancreatic ductal adenocarcinoma

Repurposing the FDA-approved anthelmintic pyrvinium pamoate for pancreatic cancer treatment: study protocol for a phase I clinical trial in early-stage pancreatic ductal adenocarcinoma

Background Recent reports of the utilisation of pyrvinium pamoate (PP), an FDA-approved anti-helminth, have shown that it inhibits pancreatic ductal adenocarcinoma (PDAC) cell growth and proliferation in-vitro and in-vivo in preclinical models. Here, we report about an ongoing phase I open-label, si...

Full description

Bibliographic Details
Main Authors: Benjamin E Leiby, Charles Yeo, James Posey, Avinoam Nevler, Harish Lavu, T Yeo, Francesca M Ponzini, Christopher W Schultz, Shawnna Cannaday, Wilbur B Bowne, Jonathan R Brody
Format: Article
Language:English
Published: BMJ Publishing Group 2023-10-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/13/10/e073839.full

Internet

https://bmjopen.bmj.com/content/13/10/e073839.full

Similar Items